Swiss National Bank Pacira Bio Sciences, Inc. Transaction History

Swiss National Bank

$150 Billion
Q3 2024

A detailed history of Swiss National Bank transactions in Pacira Bio Sciences, Inc. stock. As of the latest transaction made, Swiss National Bank holds 91,400 shares of PCRX stock, worth $1.52 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

91,400

Previous 91,400 -0.0%

Holding current value

$1.52 Million

Previous $2.61 Million 47.36%

% of portfolio

0.0%

Previous 0.0%

22 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 06, 2024	SELL	$26.32 - $34.31 $255,304 - $332,807	-9,700 Reduced 9.59%	91,400 $3.08 Million
Q3 2023 Nov 08, 2023	BUY	$30.68 - $40.09 $33,748 - $44,099	1,100 Added 1.1%	101,100 $3.1 Million
Q2 2023 Aug 09, 2023	BUY	$36.12 - $47.5 $36,120 - $47,500	1,000 Added 1.01%	100,000 $4.01 Million
Q1 2023 May 10, 2023	SELL	$35.53 - $43.38 $412,148 - $503,208	-11,600 Reduced 10.49%	99,000 $4.04 Million
Q4 2022 Feb 08, 2023	BUY	$38.19 - $57.45 $110,751 - $166,605	2,900 Added 2.69%	110,600 $4.27 Million
Q3 2022 Nov 09, 2022	BUY	$51.24 - $58.89 $122,976 - $141,336	2,400 Added 2.28%	107,700 $5.73 Million
Q1 2022 May 09, 2022	BUY	$60.03 - $76.49 $450,225 - $573,675	7,500 Added 7.67%	105,300 $8.04 Million
Q4 2021 Feb 08, 2022	BUY	$47.97 - $62.21 $28,782 - $37,326	600 Added 0.62%	97,800 $5.89 Million
Q3 2021 Nov 08, 2021	BUY	$54.64 - $61.3 $76,496 - $85,820	1,400 Added 1.46%	97,200 $5.44 Million
Q2 2021 Aug 06, 2021	BUY	$59.18 - $69.99 $88,770 - $104,984	1,500 Added 1.59%	95,800 $5.81 Million
Q1 2021 May 07, 2021	BUY	$59.31 - $78.82 $148,275 - $197,049	2,500 Added 2.72%	94,300 $6.61 Million
Q4 2020 Feb 05, 2021	BUY	$50.47 - $66.26 $55,517 - $72,886	1,100 Added 1.21%	91,800 $5.49 Million
Q3 2020 Nov 09, 2020	BUY	$51.97 - $63.0 $83,152 - $100,800	1,600 Added 1.8%	90,700 $5.45 Million
Q2 2020 Aug 05, 2020	BUY	$30.8 - $52.47 $502,040 - $855,261	16,300 Added 22.39%	89,100 $4.68 Million
Q1 2020 May 08, 2020	BUY	$28.4 - $50.7 $31,240 - $55,770	1,100 Added 1.53%	72,800 $2.44 Million
Q4 2019 Feb 06, 2020	BUY	$36.31 - $46.83 $65,358 - $84,294	1,800 Added 2.58%	71,700 $3.25 Million
Q3 2019 Nov 12, 2019	BUY	$35.66 - $44.99 $35,660 - $44,990	1,000 Added 1.45%	69,900 $2.66 Million
Q2 2019 Aug 02, 2019	SELL	$36.57 - $47.97 $219,420 - $287,820	-6,000 Reduced 8.01%	68,900 $3 Million
Q1 2019 May 10, 2019	BUY	$36.47 - $42.17 $91,175 - $105,425	2,500 Added 3.45%	74,900 $2.85 Million
Q4 2018 Feb 13, 2019	BUY	$41.31 - $52.16 $107,406 - $135,616	2,600 Added 3.72%	72,400 $3.12 Million
Q4 2017 Feb 07, 2018	BUY	$31.85 - $46.95 $85,995 - $126,765	2,700 Added 4.02%	69,800 $3.19 Million
Q3 2017 Nov 03, 2017	BUY	$35.7 - $39.5 $2.4 Million - $2.65 Million	67,100	67,100 $2.52 Million

Others Institutions Holding PCRX

# of Institutions

266

Shares Held

50.6M

Call Options Held

429K

Put Options Held

391K

View Full List

About Pacira BioSciences, Inc.

Ticker PCRX
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 45,824,200
Market Cap $761M
Description
Pacira BioSciences, Inc. provides non-opioid pain management and regenerative health solutions for healthcare practitioners and their patients in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension; and iovera system, a non-opioid ...

More about PCRX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Swiss National Bank, based on Form 13F filings with the SEC.

News

Stay updated on Swiss National Bank with notifications on news.

Account

Swiss National Bank Pacira Bio Sciences, Inc. Transaction History